Myriad to Present Eight Studies at 2014 San Antonio Breast Cancer Symposium


“We are excited to be presenting new data demonstrating that molecular diagnostics can be used to help personalize therapy for patients across the continuum of breast cancer,” said Richard Wenstrup, M.D., chief medical officer, Myriad Genetic Laboratories. “The presentation of new data for patients with breast cancer in the neoadjuvant and metastatic clinical setting underscores Myriad’s commitment to improving the lives of patients.”

Companion Diagnostics Presentations

<table>
<thead>
<tr>
<th>Title</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Podium S3-01</strong></td>
<td>The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer.</td>
</tr>
<tr>
<td><strong>Poster P3-06-11</strong></td>
<td>Homologous recombination deficiency (HRD) assay predicts response to cisplatin neoadjuvant chemotherapy in patients with triple negative breast cancer.</td>
</tr>
<tr>
<td><strong>Poster P4-11-15</strong></td>
<td>Risk Stratification within luminal B breast cancer using a second generation prognostic RNA signature.</td>
</tr>
</tbody>
</table>
Title: Poster P5-06-01: Homologous recombination deficiency (HRD) score predicts response to standard neoadjuvant chemotherapy in patients with triple negative or BRCA1/2 mutation associated breast cancer.
Presenter: Giancarlo Pruneri
Date: Friday, Dec. 12, 7:30 a.m. to 9:00 a.m. CT

Title: Poster P5-06-04: The PARP inhibitor niraparib demonstrated activity in patient-derived triple-negative breast cancer xenograft models with high homologous recombination deficiency (HRD) score.
Presenter: Melinda Telli
Date: Friday, Dec. 12, 5:00 p.m. to 7:00 p.m. CT

Title: Poster P5-06-04: The PARP inhibitor niraparib demonstrated activity in patient-derived triple-negative breast cancer xenograft models with high homologous recombination deficiency (HRD) score.
Presenter: Yan Wang
Date: Friday, Dec. 12, 5:00 p.m. to 7:00 p.m. CT

Hereditary Cancer Presentations

Title: Poster P1-03-03: Experience in community oncology practice with a 25-gene hereditary cancer panel.
Presenter: Sami Diab
Date: Wednesday, Dec. 10, 5:00 p.m. to 7:00 p.m. CT

Title: Poster P1-11-02: Telemedicine: Expanding access to cancer genetic services to underserved populations.
Presenter: Angela Bradbury
Date: Wednesday, Dec. 10, 5:00 p.m. to 7:00 p.m. CT

Title: Poster P4-12-02: Spectrum of mutations identified in a 25-gene hereditary cancer panel for patients with breast cancer.
Presenter: Lavania Sharma
Date: Friday, Dec. 12, 7:30 a.m. to 9:00 a.m. CT

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's websites: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan Lung Cancer, BRACAnalysis CDx, HRD, Vectra and Prolaris are
trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-F, MYGN-G

**Safe Harbor Statement**

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the presentation of eight new studies evaluating the use of the Company’s molecular and companion diagnostics in patients with breast cancer at the 2014 San Antonio Breast Cancer Symposium (SABCS); the presentation of studies featuring the use of companion diagnostics in patients with triple negative breast cancer; the presentation of studies highlighting new findings on the use of hereditary cancer panel testing for patients with breast cancer; the presentation of new data demonstrating that molecular diagnostics can be used to help personalize therapy for patients across the continuum of breast cancer; the presentation of new data for patients with breast cancer in the neoadjuvant, adjuvant and metastatic clinical setting; and the Company's strategic directives under the caption "About Myriad Genetics."

These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to changes in the governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial
condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our Annual Report on Form 10-K for the fiscal year ended June 30, 2014, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

###